抗生素与质子泵抑制剂对阿替利珠单抗及化疗疗效的影响:OAK与POPLAR汇总事后分析
该汇总事后分析纳入POPLAR与OAK两项随机对照试验的1512例经治晚期非小细胞肺癌患者,评估抗生素与质子泵抑制剂使用对总生存和无进展生存的影响。结果显示,在阿替利珠单抗组中,抗生素或质子泵抑制剂使用与更短的总生存相关,质子泵抑制剂使用还与更短的无进展生存相关;多因素分析显示抗生素与质子泵抑制剂与更短总生存相关;多西他赛组中未观察到类似关联。
要点
- 阿替利珠单抗组中,使用抗生素者总生存显著缩短(8.5 vs 14.1个月,HR 1.32,P=0.01)。
- 阿替利珠单抗组中,使用质子泵抑制剂者总生存(9.6 vs 14.5个月,HR 1.45,P=0.0001)及无进展生存(1.9 vs 2.8个月,HR 1.30,P=0.001)均显著缩短。
- 多西他赛组中抗生素或质子泵抑制剂使用与总生存或无进展生存无显著关联。
核心结论
- 在两项随机试验的非计划分析中,转移性非小细胞肺癌患者使用抗生素或质子泵抑制剂与不良结局相关,可能影响免疫检查点抑制剂疗效。
研究设计与样本
- 回顾性汇总分析,使用II期POPLAR(NCT01903993)和III期OAK(NCT02008227)试验数据,共纳入1512例经治非小细胞肺癌患者,随机接受阿替利珠单抗(n=757)或多西他赛(n=755)。
主要发现
- 阿替利珠单抗组169例(22.3%)和多西他赛组202例(26.8%)患者接受抗生素;两组分别有234例(30.9%)和260例(34.4%)接受质子泵抑制剂。
- 全部患者多因素分析显示,抗生素与更短总生存相关(HR 1.20,95%CI 1.04-1.39),质子泵抑制剂亦与更短总生存相关(HR 1.26,95%CI 1.10-1.44)。
- 阿替利珠单抗组中,抗生素使用者总生存缩短(8.5 vs 14.1个月,HR 1.32,95%CI 1.06-1.63,P=0.01),质子泵抑制剂使用者总生存缩短(9.6 vs 14.5个月,HR 1.45,95%CI 1.20-1.75,P=0.0001)且无进展生存缩短(1.9 vs 2.8个月,HR 1.30,95%CI 1.10-1.53,P=0.001)。
- 多西他赛组中抗生素或质子泵抑制剂使用与无进展生存或总生存无显著关联。
临床怎么用
- 对于接受阿替利珠单抗治疗的转移性非小细胞肺癌患者,应关注抗生素和质子泵抑制剂的使用,其可能与更差的生存结局相关,需权衡利弊。
局限性
- 本分析为两项随机试验的非计划事后分析,证据等级有限,需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preclinical data have shown that proton pump inhibitors (PPI) can modulate the microbiome, and single-arm studies suggested that antibiotics (ATB) may decrease the efficacy of immune checkpoint inhibitors (ICI), but randomized controlled trial data are lacking. This pooled analysis evaluated the effect of ATB and PPI on outcome in patients randomized between ICI and chemotherapy. PATIENTS AND METHODS: This retrospective analysis used pooled data from the phase II POPLAR (NCT01903993) and phase III OAK (NCT02008227) trials, which included 1512 patients with previously treated non-small-cell lung cancer (NSCLC) randomly assigned to receive atezolizumab (n = 757) or docetaxel (n = 755). The main objective of this analysis was to assess the impact of ATB and PPI use on overall survival (OS) and progression-free survival (PFS). RESULTS: A total of 169 (22.3%) patients in the atezolizumab group and 202 (26.8%) in the docetaxel group received ATB, and 234 (30.9%) and 260 (34.4%), respectively, received PPI. Multivariate analysis in all patients revealed that ATB were associated with shorter OS [hazard ratio (HR) 1.20, 95% confidence interval (CI) 1.04-1.39], as was PPI (HR 1.26, 95% CI 1.10-1.44). Within the atezolizumab population, OS was significantly shorter in patients who received ATB (8.5 versus 14.1 months, HR 1.32, 95% CI 1.06-1.63, P = 0.01) or PPI (9.6 versus 14.5 months, HR 1.45, 95% CI 1.20-1.75, P = 0.0001). PPI use was associated with shorter PFS in the atezolizumab population (1.9 versus 2.8 months, HR 1.30, 95% CI 1.10-1.53, P = 0.001). There was no association between ATB and PPI use and PFS or OS within the docetaxel population. CONCLUSION: In this unplanned analysis from two randomized trials, data suggest that ATB or PPI use in patients with metastatic NSCLC is associated with poor outcome and may influence the efficacy of ICI.
引用
- Chalabi M, Cardona A, Nagarkar DR, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020. PMID: 32115349. doi:10.1016/j.annonc.2020.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。